BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

1Crowd expands healthcare portfolio with Rymo Technologies

12 November 2026 | News

Healthcare and medtech are an important part of 1Crowd's investment portfolio, accounting for close to 20% of its investment portfolio



1Crowd, an Indian early-stage investment fund, has announced today Mumbai-based startup Rymo Technologies, a healthcare technology company focused on transforming physical rehabilitation through robotics and artificial intelligence (AI), has joined its healthcare portfolio. Rymo develops technology-led rehabilitation solutions designed to help clinicians deliver more engaging, consistent and data-driven therapy for patients recovering from neurological and orthopaedic conditions.

Rymo addresses a significant gap in India's rehabilitation ecosystem, where access to physiotherapy is limited and the adoption of robotic rehabilitation technology is still low. While imported robotic rehabilitation systems can cost between Rs 1-1.5 crore, Rymo offers 10 times more affordable solutions, making the technology more accessible to healthcare providers, especially the long tail of smaller but essential physiotherapy centres, small to mid-sized hospitals, and going as close to patients as is possible. Its focus on affordable, India-built medical technology aligns with 1Crowd's approach of backing businesses that address genuine market needs through scalable, technology-led solutions.

Rymo's product portfolio spans robotic rehabilitation systems, balance trainers, extended reality (XR) and virtual reality (VR)-based solutions, along with upcoming functional electrical stimulation (FES) devices. By combining robotics, AI and gamification, the company aims to support clinicians in providing more engaging rehabilitation programmes while enabling better tracking of patient progress. Its products are designed for use across hospitals, physiotherapy clinics and rehabilitation centres. Rymo’s products cost just 10% to 20% of what foreign competitors charge. While large metro hospitals can typically afford imported systems, mid-sized hospitals often face tighter budgets, limited space and fewer trained therapists. Rymo’s solutions are designed to address all three constraints.

Healthcare and medtech are an important part of 1Crowd's investment portfolio, accounting for close to 20% of its investment portfolio. The firm has backed around 10 companies across the broader health-tech ecosystem, including businesses in health technology, biotechnology, healthcare insurance and financing, and medical devices. Its investment in Rymo reflects its continued interest in early-stage, India-built healthcare businesses that combine technology and affordability.